Open Orphan #ORPH – Directorate Change

  Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment of Yamin ‘Mo’ Khan as an Independent Non-Executive Director to the Board of Open Orphan with immediate effect. Mo will also Chair both the Audit and Risk and […]

Open Orphan #ORPH – Controlled Human Infection Studies Report following March Webinar

Controlled Human Infection Studies: Proposals for guidance on how to design, develop and produce a challenge strain.   Report follows March Webinar run by hVIVO with HIC VAC, Wellcome Trust and IABS Highlights: Applicable local, national and regional guidelines on manufacture and use of challenge agents must be considered. As challenge agents are biological products, […]

Yahoo Finance – How Open Orphan is testing vaccines through intentional infection

Open Orphan #ORPH Executive Chairman Cathal Friel joins Yahoo Finance Live to discuss how his company is testing vaccines through intentional infection. ….ANJALEE KHEMLANI: Right, yeah, I want to get into all the potential. But let’s walk back and talk about, because the last time we spoke, you were just getting into the COVID trial. So […]

Open Orphan #ORPH – Major year-on-year revenue growth and profitable H1 2021 performance following a year of turnaround and transition in 2020

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2021. These results show a continued pattern of profitability from Q4 2020 to a firmly profitable position […]

Open Orphan #ORPH – £5.7m Influenza human challenge study contract win

Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a £5.7m contract with a specialist biotechnology company developing therapeutics for respiratory viral infections, to test its antiviral product […]

Open Orphan #ORPH – Notice of Results, Analyst Briefing and Investor Presentation

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that its interim results for the six-month period ended 30 June 2021 will be released on Monday, 20 September 2021. Analyst Briefing A briefing open to analysts will […]

Open Orphan #ORPH – Positive results from RSV Human Challenge Study

Open Orphan

RSV Human Challenge  Study conducted by hVIVO yields positive results Open Orphan plc  (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , notes the announcement dated 1 September 2021 from Barvarian Nordic A/S (OMX: BAVA), reporting positive results received from a human […]